Literature DB >> 760408

Decreased renal plasma flow during propranolol treatment in essential hypertension.

D K Falch, A E Odegaard, N Norman.   

Abstract

The pharmacodynamic effect of propranolol (80 mg b.i.d.) on the renal and systemic circulation was studied after 1 and 8 months of treatment in 13 patients with essential hypertension, using non-invasive radioisotope techniques. Effective renal plasma flow (ERPF) fell from (mean +/- S.E.M.) 244 +/- 18 to 208 +/- 14 after 1 month and to 187 +/- 13 ml/min.m2 after 8 months of treatment. Concomitantly cardiac index (CI) fell from 3.24 +/- 0.15 to 2.62 +/- 0.11 and 2.75 +/- 0.10 l/min.m2, respectively. The coefficient of correlation between the decreases in ERPF and CI was 0.49. Mean arterial blood pressure decreased from 138 +/- 5 to 118 +/- 5 and 116 +/- 4 mmHg, respectively. Left ventricular work was reduced by 30.2 and 27%, while peripheral resistance was unchanged. Total plasma volume was increased from 19.3 +/- 0.5 to 20.3 +/- 0.6 ml/cm after 1 month, but was within the same range as the control values after 8 months of treatment. Pulmonary plasma volume was unchanged, indicating that there was no pooling of plasma in the pulmonary circulation. The interventricular circulation time was increased from 6.9 +/- 0.4 s to 8.4 +/- 0.3 s and varied with the change in heart rate. It is concluded that the fall in ERPF might be explained by reduced cardiac output in addition to interference with the hemodynamic autoregulation in the kidney.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 760408     DOI: 10.1111/j.0954-6820.1979.tb06009.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  9 in total

1.  Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension.

Authors:  T Baba; S Murabayashi; K Aoyagi; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan.

Authors:  M Kohno; T Takeda; M Ishii; T Saruta; Y Mizuno; M Yoshimura; S Kubo; K Fukiyama; M Fujishima
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Beta-blockers and renal function.

Authors:  R Wilkinson
Journal:  Drugs       Date:  1982-03       Impact factor: 9.546

4.  A comparison of the effects of intravenous propranolol and nadolol on the renal response to hypertonic saline infusion.

Authors:  D G Waller; J Mihindukulasuriya; D J Warren
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

5.  Intrinsic sympathomimetic activity of cardioselective beta-adrenoceptor blockers and effects on renal function.

Authors:  I G Mackay; A M Macnicol; H J Smith; A D Cumming; M L Watson
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

6.  The effect of captopril and propranolol on the responses to posture and isometric exercise in patients with essential hypertension.

Authors:  M J Vandenburg; J M Holly; F J Goodwin; V L Sharman; F P Marsh
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Effects of captopril and nadolol on renal hemodynamics in patients with essential hypertension.

Authors:  Z H Zhu; R An; Y X Zhang; P L Gong; H Chen; F D Zen
Journal:  J Tongji Med Univ       Date:  1994

8.  Pulmonary blood volume and interventricular circulation time in physically trained and untrained subjects.

Authors:  D K Falch; S B Strømme
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1979-02-15

Review 9.  How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure.

Authors:  Holly Digne-Malcolm; Matthew C Frise; Keith L Dorrington
Journal:  Front Physiol       Date:  2016-07-29       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.